CNS Pharmaceuticals's total assets for Q2 2024 were $2.47M, an increase of 48.67% from the previous quarter. CNSP total liabilities were $6.76M for the fiscal quarter, a 11.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.